Phase I Trial of Periocular Topotecan in Retinoblastoma
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This is a dose-escalation study aimed to assess the toxicity (and marginally the activity) of
periocular topotecan in patients with relapsed-resistant retinoblastoma.